Follicular lymphoma

Annals of Oncology

Volumn 21, Issue SUPPL. 7, 2010, Pages

  Ghielmini, M ^a  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

Bendamustine; CHOP; Follicular; Lymphoma; Rituximab; Transplantation; Watch and wait

Indexed keywords

BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; INTERFERON; PREDNISONE; RITUXIMAB; VINCRISTINE;

AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CONFERENCE PAPER; DISEASE FREE SURVIVAL; DRUG EFFICACY; FOLLICULAR LYMPHOMA; HUMAN; MEDICAL DECISION MAKING; MULTIPLE MYELOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; UNSPECIFIED SIDE EFFECT; WATCHFUL WAITING; WHOLE BODY RADIATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LYMPHOMA, FOLLICULAR; NEOADJUVANT THERAPY; NITROGEN MUSTARD COMPOUNDS; WATCHFUL WAITING;

EID: 78649340121     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq287     Document Type: Conference Paper

References (15)

1. Groves FD, Linet MA, Travis LB, Devesa SS. Cancer surveillance series: non Hodgkin's lymphoma: incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000; 19: 1240-1251.
2. Fisher RI, LeBlanc M, Press OW et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23: 8447-8452
3. Keegan THM, McClure LA, Foran JM, Clarke CA. Improvements in survival after follicular lymphoma by race/ethnicity and socioeconomic status: a populationbased study. J Clin Oncol 2009; 27: 3044-3051.
4. Solal-Céligny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-1265.
5. Rohatiner AZ, Gregory WM, Peterson B et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005; 23: 2215-2223.
6. Schulz H, Bohlius JF, Trelle S et al. Immunotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99: 706-714.
7. Al-Tourah AJ, Gill KK, Chhanabhai M et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin lymphoma. J Clin Oncol 2008; 26: 5165-5169.
8. Ardenshna KM, Smith P, Norton A et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362: 516-522.
9. Peterson BA, Petroni GR, Frizzera G et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B.. J Clin Oncol 2003; 21: 5-15.
10. Rummel MJ, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009; 114: 168-169.
11. Schouten HC, Qian W, Kvaloy S et al. High-dose therapy improves progressionfree survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918-3927.
12. Ladetto M, De Marco F, Benedetti F et al. Prospective, multi center randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008; 111: 4004-4013.
13. Bierman PJ, Sweetenham JW, Loberiza FR et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation. The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003; 21: 3744-3753.
14. Feuerlein K, Zucca E, Ghielmini M. First-line treatment of follicular lymphoma -a patient-oriented algorithm. Leuk Lymphoma 2009; 50: 325-334.
15. Morschhauser F, Radford J, Van Hoof A et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26: 5156-5164.